Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
A total of 6 investors have a majority stake in the company with 55% ownership Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company To get a sense of who is truly in control of Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ), it is important to understand the ownership structure of the business. With 47% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's delve deeper into each type of owner of Monte Rosa Therapeutics, beginning with the chart below. Check out our latest analysis for Monte Rosa Therapeutics Instit
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswire
- Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice [Yahoo! Finance]Yahoo! Finance
GLUE
Earnings
- 8/8/24 - Beat
GLUE
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/7/24 - Form 10-Q
- GLUE's page on the SEC website